A panel of five mouse monoclonal antibodies (MAbs) to human recombinant steroid 21-hydroxylase (21-OH) were produced, characterized, and used to study the interaction of 21-OH autoantibodies (AAbs) with different epitopes on human 21-OH. AAbs in patients with isolated autoimmune Addison's disease, autoimmune polyglandular syndromes types I and II, and 21-OH antibody-positive patients without overt Addison's disease (25 patients in total) were studied. Four MAbs were IgG1 subclass, one was IgG2a, and all had light chains. The affinities of four of the antibodies were in the range 2.0 ϫ 10
M21-OH5 binding. In addition, MAb Fab or F(abЈ) 2 fragments were used to study 21-OH AAb epitopes in competition experiments. These investigations demonstrated that 21-OH AAbs recognize similar epitopes to the MAbs, with ER2 and ER3 being part of two distinct major epitopes, and ER 1 being part of a minor epitope. Mixtures of M21-OH antibody Fab or F(abЈ) 2 fragments caused almost complete inhibition (80%-95%) of AAb binding in 24 out of 25 sera, and in the case of the remaining serum, the effect was marked but incomplete (67% inhibition). There were no major differences between the binding characteristics of AAbs from patients with different forms of autoimmune adrenal disease. All five 21-OH MAbs reacted with human adrenal tissue in an immunofluorescence test, but only M21-OH1 and M21-OH2 reacted with bovine adrenal tissue in these experiments. None of the MAbs reacted with human ovarian tissue in an immunofluorescence test. Overall, these studies indicate that 21-OH AAbs bind to at least three different epitopes in the C-terminal part of 21-OH, and two of these epitopes appear to be human 21-OH specific. (J Clin Endocrinol Metab 83:2977-2986, 1998) T HE P450 cytochrome enzyme steroid 21-hydroxylase (21-OH), is a major autoantigen in autoimmune adrenal disease (1) (2) (3) , and measurement of 21-OH autoantibodies (AAbs) is a useful diagnostic tool in cases of suspected or overt adrenal failure (4 -7) . Furthermore, 21-OH AAbs can be helpful markers of progression towards autoimmune Addison's disease (AD) in patients with other organ-specific autoimmune disease, especially in children (8, 9) .
Previous studies have shown that AAb binding sites on 21-OH are in the main part conformational and are formed by the central and C-terminal parts of the protein (10, 11) . Furthermore, a close relationship between the parts of the sequence important for 21-OH enzyme activity and 21-OH AAb binding has been demonstrated in studies on the direct effect of 21-OH AAb on enzyme activity in vitro, and in binding studies using 21-OH containing amino acid (AA) mutations associated with reduced 21-OH enzyme activity in nonclassical adrenal hyperplasia (11) (12) (13) . Although 21-OH AAb heterogeneity was evident in these studies, there were no clear differences between 21-OH AAb binding characteristics in patients with different forms of autoimmune adrenal disease, i.e. isolated AD, AD in the context of autoimmune polyglandular syndrome (APS) types I and II, and 21-OH AAb-positive patients without overt adrenal failure (14) . To study the AAb binding epitopes on 21-OH in more detail, a panel of mouse monoclonal antibodies (MAbs) to human recombinant 21-OH was produced, and their interaction with 21-OH examined by Western blotting, immunofluorescence test (IFT), and immunoprecipitation assay (IPA). Fab or F(abЈ) 2 preparations were isolated from the 21-OH MAbs and used in binding inhibition studies. These studies allowed the identification of three different short AA sequences on 21-OH that appear to be important for parts of the AAb binding sites.
sion of the 21-OH fusion protein with glutathione-S-transferase (GST) (15) .
The full-length 21-OH gene was also cloned into pYES2.0 (Invitrogen, Leek, The Netherlands) (pYES2/21-OH1) downstream of the T7 promoter as previously described (2) . Various in-frame deletions and truncations of the 21-OH gene were carried out using different restriction enzyme sites, and the modified genes were cloned into pYES3, a derivation of pYES2, as described previously (10) . In addition, construct p21-OH14 was produced using PpumI restriction enzyme (Table 1 and Fig. 1) .
Full-length 21-OH complementary DNA was subcloned into KpnI site of pTZ18F (pND21-OH1), a derivation of the vector pTZ18R (Pharmacia Biotech). The vector pTZ18F contained a specially designed, unique linker into AccI and HindIII sites, which had stop codons in all three frames to ensure translation termination of all the inserted genes (16) . A series of 21-OH gene constructs with small stretches of gene sequence deleted (pND21-OH2-7) were generated from this construct using a Nested Deletion Kit (Pharmacia Biotech) according to the manufacturer's instructions (Table 2 and Fig. 1 ). These constructs were sequenced by the dideoxy termination method using Sequenase Version 2.0 kit according to the manufacturer's instructions (United States Biochemical, supplied by Amersham International plc, Little Chalfont, UK) using the M13 (Ϫ40) sequencing primer.
Serum samples
Sera were obtained from 21-OH AAb-positive patients (n ϭ 25) with APS type I (n ϭ 5), APS type II (n ϭ 5), isolated AD (n ϭ 5), 21-OH AAb-positive patients with normal adrenal function (potential AD; n ϭ 5), and 21-OH AAb-positive patients with impaired adrenal function (subclinical AD; n ϭ 5) ( Table 3) . Out of five patients with potential AD, three had Graves' disease, one had Hashimoto's thyroiditis, and one had insulin-dependent diabetes mellitus and premature ovarian failure (POF). Among five patients with subclinical AD, one did not have evidence of other autoimmune disease, two had Hashimoto's throiditis, one had Hashimoto's thyroiditis and POF, and one had Graves' disease. Disease diagnosis was based on clinical, immunological, and biochemical grounds (patients whose sera were used in this study have been described in detail previously, see Refs. 7 and 17). Pooled positive serum prepared from ten 21-OH AAb-positive patients with AD, with 21-OH AAb levels ranging from 7-22 U/mL (7), was used in some experiments. Pooled serum from 20 healthy blood donors was used as a 21-OH AAb-negative control. All 20 sera were negative for 21-OH AAb in the 125 I-labeled 21-OH AAb assay (7) .
Production of mouse MAbs to 21-OH
Eight-week-old female BALB/C mice were immunized with 50 g 21-OH1-GST per mouse. In the case of 21-OH7-GST, the recombinant fusion protein was treated with thrombin (Pharmacia Biotech, following manufacturer's instruction) to remove GST, and 50 g cleaved 21-OH7 protein per mouse was used for immunization. Four days after the final iv boost the mice spleen cells were fused with the myeloma cell line X63-Ag8.653 and cloned as described previously (18) 
Isolation of Fab or F(abЈ) 2 from 21-OH MAbs
21-OH MAb IgG was purified from ascites fluid by affinity chromatography on Prosep-A (Bioprocessing Ltd., Consett, UK) according to the manufacturer's instructions. MAb subclass and light chain type was determined using a commercial kit (Life Technologies, Paisley, UK).
The purified IgG preparations were treated with either pepsin (Sigma) at an enzyme/protein ratio of 1:10 or mercuripapain (Sigma) at an enzyme/protein ratio of 1:10 and passed through a Prosep-A column to remove any intact IgG or Fc fragment from the Fab or F(abЈ) 2 respectively (21).
Control IgG and Fab preparations were obtained from a TSH receptor mouse MAb (22) .
PAGE and Western blotting
Preparations of recombinant 21-OH expressed in yeast or in Escherichia coli (7) were run on 9% gels in the presence of SDS and 10 mmol/L dithiothreitol (23) and blotted onto nitrocellulose. The Western blotting procedure was carried out according to the method described by Birk and Koepsell (24) , and the membranes reacted with diluted MAb followed by antimouse Ig horseradish peroxidase conjugate and enhanced chemiluminescence reagents according to the manufacturer's instructions (Amersham International plc.). A mouse MAb to glutamic acid decarboxylase 65 was used as control (25) .
Immunofluorescence studies
The reactivity of 21-OH MAbs was also tested by a classical indirect immunofluorescence technique using thin cryosections of human and bovine adrenal tissue and biotin conjugate followed by avidin fluoresceine isothiocyanate-conjugated antimouse IgG (Sigma). Reactivity of 21-OH MAbs was also tested using cryostat sections of normal human ovary tissue by the same method. MAb IgGs were tested in serial dilutions (from 1 mg/mL to 1 ng/mL) until reaching the end point. A mouse MAb to the TSH receptor was used as a control (22) .
Reactivity of 21-OH MAbs with other steroidogenic enzymes
35 S-Labeled 17␣-OH and 35 S-labeled P450 side chain cleavage enzyme (P450scc) were prepared in the in vitro transcription/translation (TnT) system (Promega, Southampton, UK) as described previously (17 (17) to test the reactivity of the 21-OH MAbs. Rabbit antibody to 17␣-OH and P450scc were used as controls (17) . 
Analysis of reactivity of 21-OH MAb with modified 21-OH proteins
Truncation site is defined in text as number of first AA deleted. Binding of MAbs to modified 21-OH was determined by IPA using 35 S-labeled modified 21-OH. Results are expressed as positive (ϩ) or negative (Ϫ) compared with binding of a positive control (21-OH rabbit antibody; RSR Ltd.) and a negative control [a TSH receptor mouse MAb (22)]. Binding studies with each MAb to each construct were carried out in two separate experiments (each in duplicate).
TnT system and were used in IPAs to assess 21-OH MAb binding as described previously (4).
Effect of Fab or F(abЈ) 2 preparations on binding of intact monoclonal 21-OH IgG and 21-OH AAbs to 125 I-labeled 21-OH
Further analysis of the epitopes recognized by the 21-OH MAbs and by 21-OH AAb was carried out using a technique that exploits the ability of protein A to bind to intact antibody complexed with 125 I-labeled antigen but not to Fab or F(abЈ) 2 bound to labeled antigen (26) .
Fab or F(abЈ) 2 preparations, at various dilutions, were incubated for 7 h at 4 C with 125 I-labeled 21-OH (30,000 cpm/50 L). Intact 21-OH antibodies (either 50 L 21-OH MAb IgG or 50 L patient sera appropriately diluted in assay buffer) were then added and incubation continued for 18 h at 4 C.
125 I-Labeled 21-OH bound to either intact 21-OH MAb or 21-OH AAb was separated by the addition of solid-phase protein A.
Computer analysis of epitope region (ER) AA sequences
The complete complementary DNA sequences of human and bovine 21-OH (27, 28) were translated into AA sequences using the computer software DNASIS, version 2.1 (Hitachi Software Engineering America, San Francisco, CA). The AA sequences of the ERs in both human and bovine 21-OH were aligned using the Clustal method.
Statistical methods
Statistical analyses were carried out using SPSS for Windows software. The statistical significance of any difference of the effect of Fab or F(abЈ) 2 
autoimmune adrenal disease patient groups was determined by MannWhitney U test.
Results

Production of 21-OH mouse MAbs
Five mouse MAbs to 21-OH were produced; one (M21-OH1) in response to immunization with 21-OH fragment 21-OH7 and four (M21-OH2, -3, -4, and -5) in response to immunization with the full-length fusion protein 21-OH1-GST (Table 4) . Binding of the MAbs to 125 I-labeled 21-OH was dose dependent, and the antibody dilution profiles are shown in Fig. 2 . M21-OH1 was IgG2a subclass, and M21-OH2, -3, -4, and -5 were IgG1 subclass. All five antibodies had light chains (Table 4 ). Scatchard analysis of the interaction between 125 I-labeled 21-OH, and each 21-OH MAb was carried out and the affinity constants are shown in Table 4 .
Specificity of 21-OH MAbs
In Western blotting analysis, all five MAbs bound specifically to full-length 55-kDa 21-OH whether expressed in yeast or in E.coli (data not shown). M21-OH1-5 reacted with recombinant 21-OH expressed in yeast up to a dilution of 0.1 g/mL, whereas with recombinant 21-OH expressed in E.coli up to a dilution of 1 g/mL. None of the 21-OH MAbs reacted with nonrecombinant bacterial or yeast proteins (including control strains) in Western blotting analysis at these dilutions.
In addition, the reactivity of the 21-OH MAbs with a Denotes patients with POF. All patients with POF were positive for steroid-producing cell antibodies by IFT, and all these sera were also positive for 17␣-OH and/or P450scc AAbs by immunopreciptitation assay (17) . 
Immunofluorescence studies
When tested by immunofluorescence, IgGs from M21-OH1-5 reacted with human adrenal tissue, and all showed the positive staining patterns (Fig. 3 ) typical for adrenal cortex antibody (ACA). M21-OH1 was positive up to a dilution of 1 ng/mL, M21-OH2 up to a dilution of 1 g/mL, M21-OH3 up to a dilution of 100 ng/mL, M21-OH4 up to a dilution of 1 g/mL, and M21-OH5 up to a dilution of 1 g/mL. M21-OH1 and M21-OH2 showed positive staining when bovine adrenal tissue was used in IFT, whereas M21-OH3, -4, and -5 were negative in IFT based on bovine adrenal tissue (Table 4 ). All five MAbs were negative in IFT on human ovarian tissue. Control mouse IgG (from a TSH receptor MAb) was negative in immunofluorescence tests on human adrenal tissue, bovine adrenal tissue, and human ovarian tissue.
Effect of Fab or F(abЈ) 2 preparations on binding of intact monoclonal 21-OH IgGs to 125 I-labeled 21-OH
In the competition studies we originally planned to use bivalent F(abЈ) 2 preparations of the MAb. However, preliminary studies using peptic digestion showed that IgGs from M21-OH2, -3, and -4 were highly sensitive to pepsin, and all three MAbs were rapidly degraded without the formation of significant amounts of F(abЈ) 2 fragments. Consequently, F(abЈ) 2 fragments were isolated from M21-OH1 and M21-OH5, whereas Fab fragments prepared by papain digestion were obtained from M21-OH3 and the control TSH receptor MAb. These Fab and F(abЈ) 2 preparations were used in binding inhibition studies with all five MAbs. Binding of intact M21-OH1 IgG to 125 I-labeled 21-OH was inhibited by the M21-OH1 F(abЈ) 2 , whereas Fab from M21-OH3, F(abЈ) 2 from M21-OH5, and Fab from the control IgG had little or no effect (Fig. 4a) . Binding of intact M21-OH2 IgG to 125 I-labeled 21-OH was also inhibited by M21-OH1 F(abЈ) 2 , but not by M21-OH3 Fab, M21-OH5 F(abЈ) 2 and the control Fab (Fig.  4b) . Binding of intact M21-OH3 IgG to 125 I-labeled 21-OH was inhibited by M21-OH3 Fab. In contrast, M21-OH1 F(abЈ) 2 , M21-OH5 F(abЈ) 2 , and the control Fab had little or no effect (Fig. 4c) . Binding of intact M21-OH4 IgG to 125 I-labeled 21-OH was inhibited by M21-OH3 Fab, but not by M21-OH1 F(abЈ) 2 , M21-OH5 F(abЈ) 2 , and the control Fab (Fig 4d) . Binding of intact M21-OH5 IgG to 125 I-labeled 21-OH was inhibited by M21-OH5 F(abЈ) 2 , whereas M21-OH1 F(abЈ) 2 , M21-OH3 Fab, and the control Fab had little or no effect (Fig. 4e) . This data is summarized in Table 5 .
Effect of MAb Fab or F(abЈ) 2 preparations on binding of intact 21-OH AAb to 125 I-labeled 21-OH
Binding of 21-OH AAb in pooled patient sera to 125 Ilabeled 21-OH was not inhibited by M21-OH1 F(abЈ) 2 , but M21-OH3 Fab and M21-OH5 F(abЈ) 2 had clear effects (Fig.  4f) . A combination of the three Fab or F(abЈ) 2 preparations inhibited 21-OH binding by AAb almost completely (Fig. 4f) .
Fab or F(abЈ) 2 preparations from M21-OH1, -3, and -5 were also used in inhibition studies with individual 21-OH AAbpositive sera. The results of these studies are shown in Table  3 and are expressed as a percent inhibition of 125 I-labeled 21-OH binding relative to binding of AAb in the absence of Fab or F(abЈ) 2 preparations.
In the majority of patients the binding of AAb to 125 Ilabeled 21-OH was not or only partially inhibited by M21-OH1 F(abЈ) 2 with a mean inhibition of 15% Ϯ 12.7 (mean Ϯ sd, n ϭ 25; range 0 -50%). However in the case of sera from three patients (one in the APS type II group and two in the AD group) M21-OH1 F(abЈ) 2 caused inhibition of AAb binding of 50%, 30%, and 47%, respectively (Table 3) .
In contrast to M21-OH1 F(abЈ) 2 , M21-OH3 Fab resulted in clear inhibition of AAb binding to 125 I-labeled 21-OH in all 25 patient sera studied with a mean inhibition of 54% Ϯ 14.5 (mean Ϯ sd, n ϭ 25; range 27-75%) ( Table 3) .
M21-OH5 F(abЈ) 2 also showed clear inhibition of AAb binding to 125 I-labeled 21-OH in all 25 patient sera with a mean inhibition of 76% Ϯ 12.4 (mean Ϯ sd, n ϭ 25; range 35-92%) ( Table 3) .
A combination of the three Fab or F(abЈ) 2 preparations resulted in essentially complete inhibition of AAb binding to 125 I-labeled 21-OH in 24 out of 25 patients with a mean inhibition of 89.5% Ϯ 4.6 (mean Ϯ sd, n ϭ 24; range 80 -95%). However, in the case of 1 patient in the AD group, the combination of three Fab and F(abЈ) 2 preparations resulted in only 67% inhibition (Table 3) .
There were no statistical differences in the effect of each Fab or F(abЈ) 2 fragment on AAb binding between the different patient groups (P Ͼ 0.05). However when a combination of all the three Fab or F(abЈ) 2 preparations was used, there were small but statistically significant differences between the inhibition of AAb binding of the APS type II group and the potential AD group (P ϭ 0.01), the AD group and the potential AD group (P ϭ 0.01), and the subclinical AD group and the potential AD group (P ϭ 0.01); there were no statistically significant differences between the other groups (P Ͼ 0.05).
21-OH MAb epitope analysis
In the IPA based on 35 S-labeled 21-OH, all five MAbs reacted with full-length 21-OH and with 21-OH truncated at either AA 448 or 418 (from constructs p21-OH1, p21-OH2, and p21-OH3; Table 1 ). In addition, M21-OH5 reacted with 21-OH truncated at AA 381 (from construct p21-OH4) and with 21-OH with the internal deletion 382-414 AAs (from construct p21-OH12; Table 1 ). None of the 21-OH MAbs bound to 21-OH truncated at either AA 335 or AA 282 (from constructs p21-OH14 and p21-OH5, respectively; Table 1 ).
Further studies were carried out using modified 21-OH proteins, with smaller stretches of AAs deleted. All the 21-OH MAbs reacted with 21-OH with the AAs 494 -412 deleted (from constructs pND21-OH2 and pND21-OH3; Table 2). M21-OH1, -2, and -5 reacted with 21-OH with AAs 494 -406 deleted (from construct pND21-OH4; Table 2 ), whereas M21-OH3 and -4 did not react with this modified protein ( Table 2 ). M21-OH1-4 did not react with modified 21-OH proteins truncated at AA 391, 360, 340, or 335 (from constructs pND21-OH5-8, respectively; Table 2 ). In contrast, M21-OH5 bound to 21-OH proteins truncated at AAs 391, 360, or 340 but not to 21-OH truncated at AA 335 (Table 2) .
Consequently, AAs 391-405, defined as ER1 appeared important for binding of M21-OH1 and M21-OH2. AAs 406 -411 (ER2) appeared important for binding of M21-OH3 and M21-OH4, and AAs 335-339 (ER3) appeared important for binding of M21-OH5.
Computer analysis of ER sequences
Computer analysis was carried out on the AA sequences of human and bovine 21-OH to compare the sequences in the ERs 1, 2, and 3. ER1 (AA 391-405), recognized by M21-OH1 and M21-OH2, was found to be 87% homologous with two AA changes: arginine at position 400 in human 21-OH is changed to glutamine in bovine 21-OH and tryptophan at position 405 in human 21-OH is changed to arginine in bovine 21-OH (Fig. 5) . ER2 (AA 406 -411) recognized by M21-OH3 and M21-OH4, was found to be 100% homologous. ER3 (AA 335-339) recognized by M21-OH5, was found to be 80% homologous, with only one AA difference between human and bovine 21-OH: proline at position 335 in human 21-OH is changed to threonine in bovine 21-OH (Fig. 5) .
Discussion
We produced a panel of five mouse MAbs to human recombinant 21-OH (M21-OH1-5) and used them to study the epitopes for 21-OH AAbs. The MAbs were highly specific for 21-OH and did not react with 35 S-labeled 17␣-OH or P450scc in immunoprecipitation assays. Furthermore, the MAbs did not react with steroidogenic enzymes in human ovarian tissue as judged by an IFT.
Our investigations indicated that the panel of five MAbs were able to recognize three distinct sections of the 21-OH protein. M21-OH1 and -2 showed the same reactivity to one distinct part of 21-OH, M21-OH3 and -4 both reacted to another part, and M21-OH5 reacted with yet another part of the 21-OH protein sequence (Table 1 and Fig. 4 ). Although the MAbs recognized different parts of 21-OH, they showed comparable affinities for the protein ( Table 4) .
Extension of the competition studies to 21-OH AAbs in a pool of patient sera indicated that the AAbs recognized the same regions on 21-OH as the MAbs. In particular, M21-OH5 F(abЈ) 2 and M21-OH3 Fab preparations markedly inhibited the binding of 21-OH AAbs (in the patient pooled sera) to 125 I-labeled 21-OH, suggesting that these two MAbs recognize major autoantigenic epitopes on 21-OH. Further competition experiments were then carried out with 21-OH AAbs in sera from 25 individual patients with different forms of autoimmune adrenal disease. These studies showed that all the sera studied contained 21-OH AAbs that recognized the same sections of 21-OH as M21-OH3 (section 2) and M21-OH5 (section 3). M21-OH1 Fab was less effective than M21-OH3 or -5 in inhibiting the interaction between 21-OH AAbs and labeled 21-OH. A combination of Fab or F(abЈ) 2 preparations from M21-OH1, -3, and -5 inhibited 21-OH AAb binding to 125 I-labeled 21-OH essentially completely (Ͼ80%) in 24 out of the 25 sera. This suggested that essentially all the 21-OH AAbs in these 24 sera bound to the epitopes on 21-OH, which were dependent on AAs in sections 1, 2, and/or 3 of the 21-OH sequence. The single exceptional serum out of the 25 was from a patient with isolated AD, and in this case, a combination of the three Fab or F(abЈ) 2 preparations only partially inhibited 21-OH AAb binding to 125 I-labeled 21-OH (67% inhibition). Further studies with 21-OH protein truncated at AA 282 and labeled with 35 S showed that this serum recognized epitope(s) in the N-terminal part of 21-OH (data not shown), which would not be recognized by any of the five MAbs we produced. This observation is in agreement with previous studies on Western blotting of yeast expressed modified 21-OH proteins that showed that 6/14 21-OH AAbpositive sera reacted with an N-terminal epitope between AA 15 and 162 (11) . Also, Song et al. (29) reported that about 10% of 21-OH AAb-positive sera react with an epitope in bacterially expressed 21-OH N-terminal fragments (AA 1-272 ).
In the current study, no major differences were observed in the regions of 21-OH recognized by 21-OH AAbs in dif- ferent patient groups. This is in agreement with our earlier studies (14) on the reactivity of 21-OH AAbs in sera from different patient groups with full-length and modified 21-OH, and suggests that in the autoimmune response to 21-OH in APS types I and II, isolated AD, and ACA/21-OH AAbpositive patients without overt adrenal failure, the same autoantigenic epitopes are recognized. In addition, six of the patients studied (three with APS type I, one with APS type II, one with subclinical AD, and one with potential AD; Table  3 ) had POF. 21-OH AAb in sera from patients with POF showed similar binding characteristics to different regions on 21-OH as 21-OH AAb in sera from patients without POF.
The sections of 21-OH recognized by the mouse MAbs were analyzed in more detail in studies with 35 S-labeled 21-OH proteins with small segments of AAs removed ( Fig.  1 and Table 2 ). These experiments indicated that AA 391-405 were important for M21-OH1 and -2 binding, and these AAs, i.e. AA 391-405, were defined as ER1. Similarly, AA 406 -411, found to be important for M21-OH3 and -4 binding, were defined as ER2, and AA 335-339, found to be important for M21-OH5 binding, were defined as ER3. In view of the effective competition between the mouse MAbs and 21-OH AAbs ER1, ER2, and ER3 must also be an important part of the AAb binding sites. ER2 and ER3 appear to be parts of two distinct major AAb epitopes, whereas ER1 appears to be part of a minor epitope.
Further information on ER1-3 was obtained in immunofluorescence studies using human and bovine adrenal tissue sections. All five mouse MAbs reacted with human tissue, but only M21-OH1 and -2 reacted with bovine tissue. This suggested that ER2 and -3 are human specific, whereas ER1 is present on both human and bovine 21-OH. Some of the AA sequence differences between human and bovine 21-OH are consistent with this specificity. In particular, AA 335 in ER3 (AA 335-339) is the hydrophobic proline in human 21-OH and hydrophillic threonine in bovine 21-OH, and this difference is likely to have important implications for folding of ER3. Also, AA 405, immediately adjacent to ER2 (AA 406 -411) is the hydrophobic tryptophan in human 21-OH and hydrophillic arginine in bovine 21-OH, and this may be responsible for structural differences between human and bovine 21-OH in ER2. In contrast, the sequence differences between human and bovine 21-OH in ER1 are conservative and should not have a major influence on the structure of ER1. These observations emphasize the importance of using human rather than bovine adrenal tissue sections in immunofluorescence tests for adrenal AAbs. Furthermore, comparison of AA sequence homologies of 21-OH of human (27) , porcine (30) , and mouse (31) origin tends to suggest that neither porcine nor mouse would be useful substitutes for human adrenal material.
The mapping of autoantigenic epitopes using different MAbs has been used in the case of other autoantigens; for example, thyroid peroxidase, thyroglobulin, and glutamic acid decarboxylase (26, 32, 33) . However, this is the first study in the case of 21-OH, and our observations with the MAbs confirm previous reports that 21-OH AAb are heterogenous (10, 11, 13, 29) .
Previous studies (10 -13) have suggested that 21-OH AAb binding sites are conformational, and this is consistent with the nature of AAb epitopes in general (5) . In the current study we identified three short stretches of 5, 6, and 15 AAs to be involved in 21-OH AAb binding. The mouse MAbs used in these studies were raised to bacterially expressed, denatured 21-OH, and most probably bind to essentially linear epitopes, of which ER1-3 are important parts. In the case of 21-OH AAbs, the AAs contained within ER1-3 are likely to be an essential part of more complex, folded epitopes. 
M21-OH1
Fab and F(abЈ) 2 preparations from M21-OH1, -3, and -5 were used in binding inhibition studies with all five MAbs. Inhibition results are expressed ϩ ϭ inhibition, i.e. recognized the same epitope, or Ϫ ϭ no inhibition, i.e. recognized different epitope.
